Filed with the United States Patent and Trademark Office (USPTO), the U.S. patent application number US 7,674,456 B2, Priority Date: June 14, 2004, includes the following:

  1. Compositions and cell lines
  2. Therapeutic methods of using compositions of SV-BR Cells

BriaCell has obtained the exclusive license to its patent application from St. Vincent’s Medical Center, and the resulting patent will have a term extending to 2024. Hatch-Waxman extension potentially applies (additional five years).

On March 7, 2017, BriaCell filed an international patent application under the Patent Cooperation Treaty (PCT) to further expand its intellectual property portfolio underlying the Company’s current and anticipated pipeline of whole-cell cancer vaccines, including Bria-IMT™, and related companion diagnostic tests. The PCT application is designed to complement and extend on two patent applications filed by the Company with the United States Patent and Trademark Office (USPTO) in 2016, as well as the Company’s granted patent covering Bria-IMT™ (US 7,674,456 B2). The PCT patent application provides ways to generate additional whole-cell cancer vaccines and strategies for patient-specific selection of the most likely effective vaccine. BriaCell is developing its diagnostic, referred to as BriaDx™, in parallel to Bria-IMT™ in the ongoing Phase I/IIa clinical study in patients with advanced breast cancer.

Additional patent applications are expected to be filed in 2018.

Small Molecule Program
We recently disclosed the allowance by the US Patent and Trademark Office (USPTO) and also the European Patent Office (EPO) of two patent applications related to protein kinase C delta (PKCδ) inhibitor technology, titled “PKC Delta Inhibitors for use as Therapeutics”.